SCHEMBL24252436

SCHEMBL24252436

COc1ccc(CNc2cnnc3cc(-c4cc(Cl)ccc4OCC(=O)NC(C)C)ccc23)c(OC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.42
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
KDM4C Q9H3R0 2/20 0.39
ALDH1A1 P00352 6/20 0.38
CYP1A2 P05177 6/20 0.38
CYP3A4 P08684 6/20 0.38
CYP2C19 P33261 6/20 0.38
MAPT P10636 5/20 0.38
LMNA P02545 4/20 0.38
MAPK1 P28482 4/20 0.38
HSD17B10 Q99714 4/20 0.38
TSHR P16473 4/20 0.38
TP53 P04637 3/20 0.38
CYP2C9 P11712 3/20 0.38
CLK4 Q9HAZ1 2/20 0.38
HPGD P15428 2/20 0.38
CYP2D6 P10635 4/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30467679 1.00 SMN1; SMN2 (0.42) SMN1; SMN2CNR1CNR2KDM4CALDH1A1
SCHEMBL24252984 0.88 KDM4C (0.43) SMN1; SMN2CNR1CNR2KDM4CALDH1A1
SCHEMBL30451317 0.87 CYP1A2 (0.46) SMN1; SMN2CNR1CNR2KDM4CALDH1A1
SCHEMBL24252808 0.87 CYP1A2 (0.46) SMN1; SMN2CNR1CNR2KDM4CALDH1A1
Formic Acid SCHEMBL25237585 0.85 KDM4C (0.41) SMN1; SMN2CNR1CNR2KDM4CALDH1A1
SCHEMBL24252403 0.85 CNR1 (0.43) SMN1; SMN2CNR1CNR2KDM4CALDH1A1
SCHEMBL30467579 0.83 CYP1A2 (0.41) SMN1; SMN2CNR1CNR2ALDH1A1CYP1A2
SCHEMBL24252980 0.83 CYP1A2 (0.41) SMN1; SMN2CNR1CNR2ALDH1A1CYP1A2
SCHEMBL24252832 0.83 CNR1 (0.42) SMN1; SMN2CNR1CNR2KDM4CALDH1A1
SCHEMBL24252463 0.83 KDM4C (0.45) SMN1; SMN2CNR1CNR2KDM4CALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SMN1; SMN2 782/4885CNR1 2075/4885CNR2 1499/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 SMN1; SMN2 782/4885CNR1 2075/4885CNR2 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.